A higher risk of cardiovascular mortality in persons with chronic renal failure (CRF) is linked to inflammation, oxidative stress, cellular aging, and gut dysbiosis, to name a few contributing factors. According to a growing body of evidence, some dietary choices may reduce the severity of certain adverse effects. Specialized databases such as PubMed/Medline, Embase, Google Scholar, and UpToDate were searched to find published studies that focus on the pharmacological effects and mechanisms of cranberries' bioactive compounds on CRF and human health. Cranberry supplementation has been demonstrated in clinical research to offer health advantages for humans, such as reducing urinary tract infections. Recently, it has been reported that cranberry polyphenols possess anti-inflammatory and antioxidant effects and are also known to have the capacity to affect gut flora. Scientific studies on the beneficial pharmacological effects of cranberries on human health may provide an understanding of traditional cranberry therapy in chronic kidney disease and other chronic conditions. However, translational studies are needed to determine the exact dose that can be administered to humans as well as the validation of nutritional supplements that contain cranberry extract.
Ondansetron tablets that are directly compressed using crospovidone and croscarmellose as a synthetic super disintegrant are the subject of this investigation. A central composite, response surface, randomly quadratic, nonblock (version 13.0.9.0) 32 factorial design is used to optimize the formulation (two-factor three-level). To make things even more complicated, nine different formulation batches (designated as F1–F9) were created. There were three levels of crospovidone and croscarmellose (+1, 0, -1). In addition to that, pre- and postcompressional parameters were evaluated, and all evaluated parameters were found to be within acceptable range. Among all postcompressional parameter dispersion and disintegration time, in vitro drug release experiments (to quantify the amount of medication released from the tablet) and their percentage prediction error were shown to have a significant influence on three dependent variables. Various pre- and postcompression characteristics of each active component were tested in vitro. Bulk density, tap density, angle of repose, Carr’s index, and the Hausner ratio were all included in this analysis, as were many others. This tablet’s hardness and friability were also assessed along with its dimension and weight variations. Additional stability studies may be conducted using the best batch of the product. For this study, we utilised the Design-Expert software to select the formulation F6, which had dispersion times of 17.67 ± 0.03 seconds, disintegration times of 120.12 ± 0.55 seconds, and percentage drug release measurements of 99.25 ± 0.36 within 30 minutes. Predicted values and experimental data had a strong correlation. Fast dissolving pills of ondansetron hydrochloride may be created by compressing the tablets directly.
Hot melt extrusion (HME) technology was introduced to pharmaceuticals in the 1970s for manufacturing and product development. Since then, there were several developments in HME technology to utilize it effectively for the manufacturing of pharmaceuticals. Though the primary purpose of HME technology remains to be solubility enhancement through the preparation of amorphous solid dispersions, it also has various other applications like dry granulation, abuse-deterrent formulation, continuous manufacturing, film preparation, implants, sustained release formulations, etc. The purpose of this review article is to consolidate the information related to applications of HME technology in the pharmaceutical industry. Keywords: Hot melt extrusion, poorly soluble drugs, continuous manufacturing, solid orals, and applications.
Lead, a non-essential metal, enters the body in various ways, making it a major public health issue. Painters and smelters report lead poisoning in children and staff. Mining and battery workers risk lead exposure. Traditional and cultural remedies may include dangerous quantities of lead, producing lead poisoning. These drugs must be properly understood and regulated to avoid toxicity. Lead poisoning symptoms vary by duration and severity. Lead first impairs cognition, development, and behaviour by damaging the neural system. Time degrades reproductive and haematological systems. Lead's quiet entry into the body makes it deadly. Acute lead nephropathy damages kidneys at 100mg/dL. Lead levels exceeding 150mg/dL may induce encephalopathy. Blood lead levels indicate lead poisoning severity. Lead levels over 10g/dL in children and 40g/dL in adults are hazardous. Lead toxicity affects various organs. Lead may induce hypertension and cardiovascular disease. It may also cause chronic kidney disease and renal failure. Lead exposure may impede fertility, cause miscarriages, and alter foetal development; hence the reproductive system is vulnerable. Symptoms and lead levels may be treated with different approaches. Lead chelation treatment is frequent. Other vitamins and medications may enhance organ function and treat lead poisoning. Lead poisoning prevention requires widespread awareness. Strict standards and education regarding lead-contaminated products and conventional remedies should reduce occupational lead exposure. Regular blood lead level monitoring, especially in youngsters and lead workers, may help detect and treat lead poisoning early. Lead poisoning has serious health consequences. Understanding lead exposure pathways, identifying symptoms, and preventing lead poisoning is essential to public health and organ system protection.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.